Lonza: We’re making Covid vaccine as fast as we can
Portsmouth plant producing 100 million doses of key ingredient annually
Workers at Lonza Biologics’ Pease International Tradeport plan produce the active ingredient used in the Covid-19 vaccine from Moderna. (Courtesy photo)
For its part on the supply side to satisfy the demand for the Covid-19 vaccine, Lonza Biologics says it is working at capacity to satisfy its current production agreement with Moderna.
“We are aligned in delivering and releasing what has been committed,” said Lonza spokesman Glenn Myers.
The company’s agreement with Moderna is the production of 100 million doses a year at Lonza’s Portsmouth location of the active ingredient used in the Moderna vaccine. Initial production started in May.
Moderna itself has a small manufacturing facility in Norwood, Mass.
Myers also noted Lonza is responsible for one phase in the production of the vaccine.
“The final output of patient doses does not only depend on drug substance manufacturing, but also on fill and finish,” he said.
Continue reading at SeacoastOnline.com.
This article is being shared by partners in the Granite State News Collaborative. For more information, visit collaborativenh.org.
